ErbB2 immune response in breast cancer patients with soluble receptor ectodomain (Q35809954)

10 August 2017

ErbB2 immune response in breast cancer patients with soluble receptor ectodomain (English)

1 reference

10 August 2017

V Visco

1

1 reference

10 August 2017

R Bei

2

1 reference

10 August 2017

E Moriconi

3

1 reference

10 August 2017

W Gianni

4

1 reference

10 August 2017

M H Kraus

5

1 reference

10 August 2017

R Muraro

6

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

The American Journal of Pathology

10 August 2017

1 reference

10 August 2017

156

1 reference

10 August 2017

4

1 reference

10 August 2017

1417-1424

1 reference

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

The biology of erbB-2/neu/HER-2 and its role in cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Fas ligation induces apoptosis of CD40-activated human B lymphocytes

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Immunity to Oncogenic Proteins

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Molecular cloning and expression of an additional epidermal growth factor receptor-related gene

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Induction of anti-self-immunity to cure cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1876881

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

25 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

C-erbB-2 protein in the sera of breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Detection of C-ERBB-2 Related Protein in Sera from Breast Cancer Patients Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Immune responses to all ErbB family receptors detectable in serum of cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Positive selection of natural autoreactive B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2965010-9

Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer

7 January 2021

1 reference

12 December 2020

Increased erbB-2 gene copies and expression in multiple stages of breast cancer

1 reference

12 December 2020

The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage

1 reference

12 December 2020

Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1

1 reference

12 December 2020

C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis

1 reference

12 December 2020

10.1016/S0002-9440(10)65010-9

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

10751365

1 reference